Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives

J Control Release. 2016 Oct 28:240:489-503. doi: 10.1016/j.jconrel.2016.06.012. Epub 2016 Jun 8.

Abstract

Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy.

Keywords: Cancer therapy; Nanomedicine; Perspectives; Strategies; Synergistic drug combinations.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Drug Carriers / chemistry*
  • Drug Synergism
  • Genetic Therapy / methods
  • Humans
  • Nanomedicine / methods*
  • Nanomedicine / trends
  • Nanostructures / chemistry*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics

Substances

  • Drug Carriers